Sequence: FITC-Ahx-WIFPWIQL-GG-RRRRRRRRR-GG
| Experiment Id | EXP001274 |
|---|---|
| Paper | Cancer-Targeting Peptides Functionalized With Polyarginine Enables GRP78-Dependent Cell Uptake and s |
| Peptide | W1-R9 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 10 µM (uptake imaging); transfection complexes prepared at 5:1 N:P |
| Rna Concentration | 15–50 nM (transfection; 25 nM commonly used) |
| Mixing Ratio | 5:1 N:P (peptide:siRNA); CaCl2 20 mM used in optimized formulation |
| Formulation Format | peptide:siRNA complexes (CaCl2-condensed nanoparticles; TEM) |
| Formulation Components | W1-R9 peptide + GRP78 siRNA + CaCl2 (20 mM) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | DU145; WI-38 |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro uptake + GRP78 knockdown |
| Output Value | |
| Output Units | |
| Output Notes | GRP78-dependent uptake shown (inhibition with anti-GRP78 antibody; confocal/flow cytometry). Peptide:siRNA complexes (5:1 N:P) condensed into nanoparticles with CaCl2 (20 mM) and used for GRP78 siRNA delivery; GRP78 mRNA/protein knockdown measured by qRT-PCR and Western blot (Fig. S8–S10). |
| Toxicity Notes | MTT viability assay performed in DU145 and WI-38 at 0–100 µM peptide (Fig. S2, ESI). |
| Curation Notes |